{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines MutS : Questions médicales les plus fréquentes",
"headline": "Protéines MutS : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines MutS : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-25",
"dateModified": "2025-03-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines MutS"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de liaison à l'ADN",
"url": "https://questionsmedicales.fr/mesh/D004268",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de liaison à l'ADN",
"code": {
"@type": "MedicalCode",
"code": "D004268",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.260"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine MutS de liaison aux mésappariements de l'ADN",
"alternateName": "MutS DNA Mismatch-Binding Protein",
"url": "https://questionsmedicales.fr/mesh/D051719",
"about": {
"@type": "MedicalCondition",
"name": "Protéine MutS de liaison aux mésappariements de l'ADN",
"code": {
"@type": "MedicalCode",
"code": "D051719",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.260.556.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine-3 homologue de MutS",
"alternateName": "MutS Homolog 3 Protein",
"url": "https://questionsmedicales.fr/mesh/D000074081",
"about": {
"@type": "MedicalCondition",
"name": "Protéine-3 homologue de MutS",
"code": {
"@type": "MedicalCode",
"code": "D000074081",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.260.556.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines MutS",
"alternateName": "MutS Proteins",
"code": {
"@type": "MedicalCode",
"code": "D000074080",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Taiki Futagami",
"url": "https://questionsmedicales.fr/author/Taiki%20Futagami",
"affiliation": {
"@type": "Organization",
"name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan. Electronic address: futagami@agri.kagoshima-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Kayu Okutsu",
"url": "https://questionsmedicales.fr/author/Kayu%20Okutsu",
"affiliation": {
"@type": "Organization",
"name": "Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan."
}
},
{
"@type": "Person",
"name": "Yumiko Yoshizaki",
"url": "https://questionsmedicales.fr/author/Yumiko%20Yoshizaki",
"affiliation": {
"@type": "Organization",
"name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan."
}
},
{
"@type": "Person",
"name": "Kazunori Takamine",
"url": "https://questionsmedicales.fr/author/Kazunori%20Takamine",
"affiliation": {
"@type": "Organization",
"name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan."
}
},
{
"@type": "Person",
"name": "Hisanori Tamaki",
"url": "https://questionsmedicales.fr/author/Hisanori%20Tamaki",
"affiliation": {
"@type": "Organization",
"name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The ERBB2 Exonic Variant Pro1170Ala Modulates Mitogen-Activated Protein Kinase Signaling Cascades and Associates with Allergic Asthma.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37336194",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000530960"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lysophosphatidic Acid Stimulates Mitogenic Activity and Signaling in Human Neuroblastoma Cells through a Crosstalk with Anaplastic Lymphoma Kinase.",
"datePublished": "2024-05-28",
"url": "https://questionsmedicales.fr/article/38927035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biom14060631"
}
},
{
"@type": "ScholarlyArticle",
"name": "Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.",
"datePublished": "2024-04-30",
"url": "https://questionsmedicales.fr/article/38687926",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/jcrt.jcrt_1504_23"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes.",
"datePublished": "2023-03-27",
"url": "https://questionsmedicales.fr/article/36973520",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00401-023-02561-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy.",
"datePublished": "2024-06-01",
"url": "https://questionsmedicales.fr/article/38918683",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31557/APJCP.2024.25.6.2193"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines de liaison à l'ADN",
"item": "https://questionsmedicales.fr/mesh/D004268"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines MutS",
"item": "https://questionsmedicales.fr/mesh/D000074080"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines MutS - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines MutS",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines MutS",
"description": "Comment diagnostiquer une déficience en protéines MutS ?\nQuels tests sont utilisés pour évaluer l'activité des protéines MutS ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels symptômes peuvent indiquer un problème avec MutS ?\nY a-t-il des marqueurs biologiques associés à MutS ?",
"url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=MAP+Kinase+Signaling+System&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines MutS",
"description": "Quels sont les symptômes d'une mutation de MutS ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes varient-ils selon les individus ?\nLes symptômes peuvent-ils apparaître tardivement ?\nY a-t-il des symptômes associés à d'autres maladies ?",
"url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=MAP+Kinase+Signaling+System&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines MutS",
"description": "Comment prévenir les cancers liés à MutS ?\nLes changements de mode de vie aident-ils ?\nLes tests génétiques sont-ils recommandés ?\nY a-t-il des recommandations alimentaires ?\nLes vaccinations peuvent-elles aider ?",
"url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=MAP+Kinase+Signaling+System&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines MutS",
"description": "Quels traitements sont disponibles pour les cancers liés à MutS ?\nLa thérapie génique est-elle une option ?\nComment la surveillance est-elle effectuée ?\nY a-t-il des traitements préventifs ?\nLes traitements ciblés sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=MAP+Kinase+Signaling+System&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines MutS",
"description": "Quelles complications peuvent survenir avec MutS ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications psychologiques ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=MAP+Kinase+Signaling+System&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines MutS",
"description": "Quels sont les principaux facteurs de risque liés à MutS ?\nL'âge est-il un facteur de risque ?\nLe sexe influence-t-il le risque ?\nLes habitudes de vie jouent-elles un rôle ?\nY a-t-il des facteurs environnementaux à considérer ?",
"url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=MAP+Kinase+Signaling+System&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en protéines MutS ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent identifier des mutations dans les gènes codant pour MutS."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des protéines MutS ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de réparation de l'ADN in vitro peuvent mesurer l'activité des protéines MutS."
}
},
{
"@type": "Question",
"name": "Les biopsies peuvent-elles aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biopsies tumorales peuvent révéler des anomalies dans les protéines MutS."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec MutS ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de cancer héréditaire peuvent suggérer une déficience en MutS."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques associés à MutS ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certains biomarqueurs peuvent indiquer une dysfonction de MutS."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une mutation de MutS ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mutations peuvent entraîner des cancers, notamment le cancer colorectal héréditaire."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains individus porteurs de mutations peuvent ne pas présenter de symptômes visibles."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon les individus ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent varier en fonction de l'âge et de l'historique familial."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils apparaître tardivement ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains cancers liés à MutS peuvent se développer plus tard dans la vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés à d'autres maladies ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes similaires peuvent être observés dans d'autres syndromes de cancer héréditaire."
}
},
{
"@type": "Question",
"name": "Comment prévenir les cancers liés à MutS ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut des dépistages réguliers et des conseils génétiques pour les familles."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de cancer, même avec des mutations."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent aider à identifier les individus à risque élevé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations alimentaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en fibres et en antioxydants est conseillée pour la prévention."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations, comme contre le HPV, peuvent réduire le risque de cancers associés."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les cancers liés à MutS ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la chimiothérapie et l'immunothérapie."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore une option standard pour MutS."
}
},
{
"@type": "Question",
"name": "Comment la surveillance est-elle effectuée ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière par des examens endoscopiques est recommandée pour les porteurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interventions chirurgicales prophylactiques peuvent être envisagées pour réduire le risque."
}
},
{
"@type": "Question",
"name": "Les traitements ciblés sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés sont en développement et montrent des résultats prometteurs."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec MutS ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent un risque accru de divers cancers et des syndromes associés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en raison des traitements et des symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications psychologiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diagnostic de mutations MutS peut entraîner de l'anxiété et du stress."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière et des interventions précoces peuvent aider à prévenir certaines complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque liés à MutS ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de cancer et les mutations génétiques sont des facteurs clés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de cancer augmente avec l'âge, surtout chez les porteurs de mutations MutS."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations peuvent avoir un impact différent selon le sexe, affectant le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie jouent-elles un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie malsaines peuvent augmenter le risque de cancer chez les porteurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains agents cancérigènes peut augmenter le risque chez les porteurs de MutS."
}
}
]
}
]
}
Previous studies have indicated the ERBB2 genetic variants in the 17q12 locus might be associated with asthma; however, the functional effects of these variants on asthma risk remain inconclusive. Thi...
This study belongs to a part of an ongoing Singapore/Malaysia cross-sectional genetics and epidemiological study (SMCSGES). Genotype-phenotype associations were assessed by performing a genotyping ass...
The ERBB2 tag-SNP rs1058808 was significantly associated with allergic asthma, with the allele "G" identified as protective against the disease (adjusted logistic p = 6.56 × 10-9, OR = 0.625, 95% CI: ...
The present findings highlighted the involvement of a functional exonic variant of ERBB2 in asthma development via modulating the MAPK signaling cascade....
Lysophosphatidic acid (LPA) is a well-documented pro-oncogenic factor in different cancers, but relatively little is known on its biological activity in neuroblastoma. The LPA effects and the particip...
This study aimed to investigate BVD-523 (ulixertinib), an adenosine triphosphate (ATP)-dependent extracellular signal-regulated kinases 1/2 inhibitor, for its antitumor potential in thyroid cancer....
Ten thyroid cancer cell lines known to carry mitogen-activated protein kinase (MAPK)-activated mutations, including v-Raf murine sarcoma viral oncogene homolog B (BRAF) and rat sarcoma virus (RAS) mut...
BVD-523 significantly inhibited thyroid cancer cell proliferation and induced G1/S cell cycle arrest dose-dependently. Notably, cell lines carrying MAPK mutations, especially those with the BRAF V600E...
This study reveals the potent antitumor activity of BVD-523 against thyroid cancer cells bearing MAPK-activating mutations, offering promise for treating aggressive forms of thyroid cancer....
Exome-wide sequencing studies recently described PTPN11 as a novel brain somatic epilepsy gene. In contrast, germline mutations of PTPN11 are known to cause Noonan syndrome, a multisystem disorder cha...
The alterations of EGFR and HER2/neu as growth factor receptors and the cytoplasmic signal transduction proteins of RAS/RAF/MAP kinases including its end effector molecule (ERK) are important in the c...
Immunohistochemistry- using tissue microarrays- for EGFR, HER2/neu, non-phosphorylated, and phosphor-ERK, was performed on tissues from 166 patients- with primary prostatic adenocarcinoma with no prio...
The prostatic tissue showed EGFR, HER2 neu, phosphorylated and non-phosphorylated ERK expression in 8.4%, 1.4%, 78.2%, and 83.4% respectively whether low (patchy) or high expression (diffuse). There w...
EGFR and HER2/neu may play a limited role in prostatic adenocarcinoma as they showed positive expression in a limited number of the examined tissues specifically HER2neu. The expression of non-phospho...
Cannabidiol exerts its anti-inflammatory and anti-oxidant activities in various human cells. However, its proliferative effect has not been extrapolated to human gingival fibroblasts (HGFs). This stud...
HGFs, characterized by their CD73, CD90, and CD105 expressions by flow cytometry, were treated with cannabidiol at 0.01-30 μM. The cytotoxicity was determined by the MTT assay, while the proliferative...
No toxicity was found in HGFs treated with any doses of cannabidiol up to 30 μM. The mean percentage of cell proliferation was significantly enhanced by treatment with cannabidiol at 3 or 10 μM (p < ....
Treatment with cannabidiol at non-toxic doses promotes HGFs' proliferation and migration....
The receptor tyrosine kinase ephrin type-A receptor 2 (EphA2) is overexpressed in malignant tumors. We previously reported that non-canonical EphA2 phosphorylation at Ser-897 was catalyzed by p90 ribo...
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy with poor prognosis and dismal patient survival. Although protein kinase D (PKD) isoforms, especially PKD2 and PKD3 are cri...
Extracellular signal-regulated protein kinase 1/2 (ERK1/2), the only known substrate of MEK1/2, is located downstream of the RAS-RAF-MEK-ERK (MAPK) pathway and is associated with the abnormal activati...
Anaplastic thyroid cancer (ATC) is one of the deadliest and most aggressive human malignancies for which there is currently no effective treatment. Tyrosine kinase receptor RON is highly expressed in ...